Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Pfizer reports that Prevenar 13 Phase 3 study meets all primary, secondary objectives

21:03 EDT 28 Apr 2013 | News-Medical.net

Pfizer Inc. presented today the results from a Phase 3 study investigating immunogenicity, tolerability and safety of Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) in adults 18 to 49 years of age.

Original Article: Pfizer reports that Prevenar 13 Phase 3 study meets all primary, secondary objectives

NEXT ARTICLE

More From BioPortfolio on "Pfizer reports that Prevenar 13 Phase 3 study meets all primary, secondary objectives"

Search BioPortfolio:
Advertisement
Advertisement

Searches Linking to this Story